再鼎医药今日盘中大涨5.11%，引起了市场的广泛关注。
消息面上，再鼎医药近日宣布，美国FDA已授予其具有同类首创潜力的靶向Delta样配体3的抗体药物偶联物zocilurtatug pelitecan快速通道资格认定，用于治疗在接受一线标准治疗后出现疾病进展的epNECs。快速通道资格有助于加速药物审评进程，体现FDA对该适应症未满足临床需求的认可。此外，公司于5月12日披露根据2024年股权激励计划授出13.68万份购股权及7.53万份受限制股份单位，涉及相关股份合计超212万股。
再鼎医药所在的生物科技行业中，个股表现分化，信达生物涨2.76%，百济神州涨0.05%，三生制药跌0.38%，映恩生物跌0.41%，康方生物跌1.18%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.